{
    "clinical_study": {
        "@rank": "129654", 
        "brief_summary": {
            "textblock": "To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment\n      for biopsy proven fungal infections in major organs, disseminated infection, suspected\n      fungal infection and fungemia in adult neutropenic and non-neutropenic patients without\n      AIDS, AIDS related complex (ARC), or extensive burns. HIV seropositive patients are allowed\n      only if they also have a malignancy."
        }, 
        "brief_title": "A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections", 
        "condition": [
            "Mycoses", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Mycoses"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Immunostimulants under studies carried out under an IRB approved protocol.\n\n          -  Treatments of intercurrent non-fungal infection.\n\n          -  Allowed but requires monitoring during fluconazole therapy:\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Oral hypoglycemics.\n\n          -  Coumarin-type anticoagulants.\n\n        Patients must have the following:\n\n          -  Diagnosis or presumption of fungal infection under defined conditions.\n\n          -  Written informed consent either from the patient or the patient's legal guardian.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Burns > 30 percent of the body.\n\n          -  Diagnosis of AIDS or AIDS related complex (ARC).\n\n          -  HIV positive unless they have a malignancy.\n\n          -  History of allergy to or intolerance of imidazoles or azoles.\n\n          -  Moderate to severe liver disease as defined by specific lab values.\n\n          -  Unlikely to survive more than 24 hours.\n\n          -  Evidence of previous amphotericin B sensitivity.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concomitant antifungal agents other than the study drugs.\n\n          -  Immunostimulants, except for studies carried out under an IRB approved protocol.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacements.\n\n        Patients with the following are excluded:\n\n          -  Defined disease conditions listed in Exclusion Co-Existing Conditions.\n\n          -  Unlikely to survive more than 24 hours.\n\n          -  Previous participation in this study; reentry for the same infection is not allowed.\n\n          -  Known to be unable to take amphotericin B due to acute toxicities.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Previous fluconazole therapy for this infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002277", 
            "org_study_id": "012N", 
            "secondary_id": "056-173"
        }, 
        "intervention": [
            {
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amphotericin B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Fluconazole"
            ]
        }, 
        "keyword": [
            "Mycoses", 
            "Neoplasms", 
            "Neutropenia", 
            "Fluconazole", 
            "Amphotericin B"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "M D Anderson Cancer Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Dr Layne Gentry"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Dr Temple Williams"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Fluconazole Versus Amphotericin B: A Prospective, Randomized, Multicenter Study for Therapy of Fungal Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002277"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1993"
    }, 
    "geocoordinates": {
        "Dr Layne Gentry": "29.76 -95.369", 
        "Dr Temple Williams": "29.76 -95.369", 
        "M D Anderson Cancer Ctr": "29.76 -95.369"
    }
}